Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Dow
Baxter
QuintilesIMS
Cipla
Chubb
Covington
Colorcon

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021434

« Back to Dashboard

NDA 021434 describes XANAX XR, which is a drug marketed by Pharmacia And Upjohn and is included in one NDA. It is available from three suppliers. Additional details are available on the XANAX XR profile page.

The generic ingredient in XANAX XR is alprazolam. There are fifteen drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the alprazolam profile page.
Summary for 021434
Tradename:XANAX XR
Applicant:Pharmacia And Upjohn
Ingredient:alprazolam
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021434
Ingredient-typeBenzodiazepines
Medical Subject Heading (MeSH) Categories for 021434
Suppliers and Packaging for NDA: 021434
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
XANAX XR alprazolam TABLET, EXTENDED RELEASE;ORAL 021434 NDA Pharmacia and Upjohn Company LLC 0009-0057 N 0009-0057-07
XANAX XR alprazolam TABLET, EXTENDED RELEASE;ORAL 021434 NDA Pharmacia and Upjohn Company LLC 0009-0059 N 0009-0059-07

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength0.5MG
Approval Date:Jan 17, 2003TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength1MG
Approval Date:Jan 17, 2003TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength2MG
Approval Date:Jan 17, 2003TE:ABRLD:Yes

Expired US Patents for NDA 021434

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn XANAX XR alprazolam TABLET, EXTENDED RELEASE;ORAL 021434-001 Jan 17, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn XANAX XR alprazolam TABLET, EXTENDED RELEASE;ORAL 021434-004 Jan 17, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn XANAX XR alprazolam TABLET, EXTENDED RELEASE;ORAL 021434-002 Jan 17, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn XANAX XR alprazolam TABLET, EXTENDED RELEASE;ORAL 021434-003 Jan 17, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Colorcon
Cantor Fitzgerald
Julphar
Queensland Health
Fuji
Argus Health
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot